28.25 USD
-0.53 (-1.84%)
29 USD
+0.75 (+2.65%)
Taking everything into account, CAI scores 3 out of 10 in our fundamental rating. CAI was compared to 530 industry peers in the Biotechnology industry. The financial health of CAI is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CAI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CAI had negative earnings in the past year.
1.2 Ratios
With a Return On Assets value of -101.38%, CAI is not doing good in the industry: 74.91% of the companies in the same industry are doing better.
The Return On Equity of CAI (-208.66%) is worse than 68.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.38% | ||
| ROE | -208.66% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CAI has a Gross Margin of 53.54%. This is in the better half of the industry: CAI outperforms 76.42% of its industry peers.
CAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAI remains at a similar level compared to 1 year ago.
The number of shares outstanding for CAI has been increased compared to 5 years ago.
CAI has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.58 indicates that CAI is not in any danger for bankruptcy at the moment.
CAI has a better Altman-Z score (6.58) than 75.85% of its industry peers.
CAI has a Debt/Equity ratio of 0.79. This is a neutral value indicating CAI is somewhat dependend on debt financing.
CAI has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: CAI underperforms 72.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.58 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
A Current Ratio of 9.93 indicates that CAI has no problem at all paying its short term obligations.
CAI has a Current ratio of 9.93. This is amongst the best in the industry. CAI outperforms 80.75% of its industry peers.
CAI has a Quick Ratio of 9.36. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.36, CAI is doing good in the industry, outperforming 79.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.93 | ||
| Quick Ratio | 9.36 |
3. Growth
3.1 Past
CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
Looking at the last year, CAI shows a very strong growth in Revenue. The Revenue has grown by 34.67%.
The Revenue has been growing slightly by 6.64% on average over the past years.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CAI will show a very negative growth in Earnings Per Share. The EPS will decrease by -36.08% on average per year.
The Revenue is expected to grow by 30.73% on average over the next years. This is a very strong growth
EPS Next Y-132.57%
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%
EPS Next 5Y-36.08%
Revenue Next Year76.15%
Revenue Next 2Y54.33%
Revenue Next 3Y42.64%
Revenue Next 5Y30.73%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 149.49, the valuation of CAI can be described as expensive.
88.30% of the companies in the same industry are more expensive than CAI, based on the Price/Forward Earnings ratio.
CAI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 149.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CAI's earnings are expected to decrease with -58.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%
5. Dividend
5.1 Amount
No dividends for CAI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.25
-0.53 (-1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners37.15%
Inst Owner Change0%
Ins Owners48.47%
Ins Owner Change-1.36%
Market Cap7.97B
Revenue(TTM)931.41M
Net Income(TTM)-998.17M
Analysts86.67
Price Target38.42 (36%)
Short Float %4.68%
Short Ratio2.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1853.44%
Min EPS beat(2)-3845.54%
Max EPS beat(2)138.66%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)28.77%
Min Revenue beat(2)26.17%
Max Revenue beat(2)31.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.34%
PT rev (3m)-3.73%
EPS NQ rev (1m)13.66%
EPS NQ rev (3m)29.1%
EPS NY rev (1m)9.15%
EPS NY rev (3m)12.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)7.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 149.49 | ||
| P/S | 8.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.66 | ||
| P/tB | 17.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.58
EYN/A
EPS(NY)0.19
Fwd EY0.67%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.3
BVpS1.7
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.38% | ||
| ROE | -208.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.54% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.93 | ||
| Quick Ratio | 9.36 | ||
| Altman-Z | 6.58 |
F-ScoreN/A
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-132.57%
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%
EPS Next 5Y-36.08%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year76.15%
Revenue Next 2Y54.33%
Revenue Next 3Y42.64%
Revenue Next 5Y30.73%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.82%
EBIT Next 3Y47.6%
EBIT Next 5Y30.65%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A
CARIS LIFE SCIENCES INC / CAI FAQ
What is the fundamental rating for CAI stock?
ChartMill assigns a fundamental rating of 3 / 10 to CAI.
Can you provide the valuation status for CARIS LIFE SCIENCES INC?
ChartMill assigns a valuation rating of 1 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Overvalued.
Can you provide the profitability details for CARIS LIFE SCIENCES INC?
CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CAI stock?
The Earnings per Share (EPS) of CARIS LIFE SCIENCES INC (CAI) is expected to decline by -132.57% in the next year.